Register for email alerts and news feeds:
This journal | BMJ Group
rss
Journal of Neurology, Neurosurgery, and Psychiatry 2003;74:944-945; doi:10.1136/jnnp.74.7.944
Copyright © 2003 by the BMJ Publishing Group Ltd.
Journal of Neurology Neurosurgery and Psychiatry 2003;74:944-945
© 2003 BMJ Publishing Group

SHORT REPORT

The role of the PTPRC (CD45) mutation in the development of multiple sclerosis in the North West region of the United Kingdom

R S Nicholas1, J Partridge3, R P Donn2, C Hawkins3 and M D Boggild1

1 The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool, UK
2 ARC Epidemiology Research Unit, University of Manchester, UK
3 North Staffordshire Royal Infirmary, Princes Road, Hartshill, Stoke-on-Trent, UK

Correspondence to:
Correspondence to:
Dr Richard Nicholas, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7JL, UK;
rnichola{at}liv.ac.uk

ABSTRACT

Background: A point mutation in protein tyrosine phosphatase receptor, type c polypeptide (PTPRC) has been associated with familial multiple sclerosis. This CG mutation at position 77 of exon 4 results in altered expression of CD45 isoforms on immune cells.

Objective: To study the incidence of PTPRC mutations in subjects with multiple sclerosis in the North West region of the United Kingdom.

Methods: Affected and unaffected subjects from five pedigrees with familial multiple sclerosis, 330 non-familial cases of multiple sclerosis, and 197 controls were studied. Genomic DNA was amplified using CD45IE34 and CD45IE44 primers, digested with Mspl, and run on an agarose gel. Polymerase chain reaction products were sequenced to exclude any other mutations.

Results: No PTPRC exon 4 genomic mutations were seen in any of the five families. In the non-familial cases the incidence of mutation was 4.1% in 197 controls and 5.1% in 330 multiple sclerosis patients. No significant association was found in this study with this mutation and disease susceptibility, sex, or an extended disability scale score of < 5.5.

Conclusions: This candidate does not appear to influence the development of familial multiple sclerosis in this population. The negative result could arise from a type II error owing to the number of families and non-familial cases screened. Alternatively it might suggest that the contribution of the PTPRC mutation depends upon the genetic background.

Keywords: CD45; genetics; multiple sclerosis


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Vyshkina, T., Leist, T. P, Shugart, Y. Y., Kalman, B. (2004). CD45 (PTPRC) as a candidate gene in multiple sclerosis. Mult Scler 10: 614-617 [Abstract]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest neurology and neurosurgery jobs

Neurology and neurosurgery jobs